Elsevier

JAAD International

Volume 6, March 2022, Pages 107-108
JAAD International

Research letter
Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine

https://doi.org/10.1016/j.jdin.2021.12.009Get rights and content
Under a Creative Commons license
open access

keywords

BNT162b2
COVID-19
drug eruption
erythema nodosum
Pfizer-BioNTech
vaccine

Cited by (0)

Funding sources: None.

IRB approval status: Not applicable.

Key words: BNT162b2; COVID-19; drug eruption; erythema nodosum; Pfizer-BioNTech; vaccine.

© 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.